Brokers Offer Predictions for OPKO Health FY2028 Earnings

OPKO Health, Inc. (NASDAQ:OPK) – Stock analysts at Barrington Research upped their FY2028 earnings per share (EPS) estimates for shares of OPKO Health in a report released on Friday, November 8th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will post earnings of $0.00 per share for the year, up from their previous estimate of ($0.01). Barrington Research currently has a “Outperform” rating and a $2.25 target price on the stock. The consensus estimate for OPKO Health’s current full-year earnings is ($0.29) per share.

OPK has been the topic of several other research reports. Piper Sandler reissued an “overweight” rating and set a $3.00 target price on shares of OPKO Health in a research report on Tuesday, September 17th. HC Wainwright reissued a “buy” rating and set a $3.00 target price on shares of OPKO Health in a research report on Thursday, September 26th. Finally, StockNews.com raised OPKO Health to a “sell” rating in a research report on Saturday, July 27th.

OPKO Health Stock Performance

NASDAQ OPK opened at $1.61 on Monday. The company has a market cap of $1.12 billion, a P/E ratio of -8.47 and a beta of 1.65. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.36 and a current ratio of 1.63. The business’s 50 day moving average price is $1.51 and its 200-day moving average price is $1.43. OPKO Health has a fifty-two week low of $0.85 and a fifty-two week high of $1.75.

Institutional Investors Weigh In On OPKO Health

Hedge funds have recently made changes to their positions in the company. CIBC Asset Management Inc lifted its stake in shares of OPKO Health by 79.1% during the 2nd quarter. CIBC Asset Management Inc now owns 20,322 shares of the biotechnology company’s stock worth $25,000 after purchasing an additional 8,978 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of OPKO Health during the 1st quarter worth $26,000. Algert Global LLC purchased a new stake in shares of OPKO Health during the 2nd quarter worth $44,000. Headlands Technologies LLC purchased a new stake in shares of OPKO Health during the 1st quarter worth $47,000. Finally, Private Advisor Group LLC lifted its stake in shares of OPKO Health by 242.7% during the 3rd quarter. Private Advisor Group LLC now owns 35,301 shares of the biotechnology company’s stock worth $53,000 after purchasing an additional 25,000 shares during the last quarter. 64.63% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at OPKO Health

In other OPKO Health news, CEO Phillip Md Et Al Frost acquired 280,183 shares of the business’s stock in a transaction on Friday, November 8th. The shares were bought at an average price of $1.50 per share, with a total value of $420,274.50. Following the transaction, the chief executive officer now directly owns 211,512,405 shares of the company’s stock, valued at $317,268,607.50. The trade was a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this link. In other news, CEO Phillip Md Et Al Frost bought 280,183 shares of the stock in a transaction on Friday, November 8th. The stock was acquired at an average cost of $1.50 per share, for a total transaction of $420,274.50. Following the acquisition, the chief executive officer now owns 211,512,405 shares of the company’s stock, valued at $317,268,607.50. This represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, major shareholder Opko Health, Inc. sold 39,824 shares of the company’s stock in a transaction on Thursday, August 15th. The stock was sold at an average price of $33.08, for a total value of $1,317,377.92. Following the completion of the sale, the insider now owns 2,746,972 shares of the company’s stock, valued at $90,869,833.76. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 47.26% of the stock is currently owned by corporate insiders.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.